Significant Ownership of Invus Global Management, LLC

Signature - Title
/s/ Raymond Debbane - Raymond Debbane, President
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Invus Global Management, LLC.

Follow Filing Activity

Follow Invus Global Management, LLC and return when a new Schedule 13D/G filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sign up to follow filing activity

Sponsored

Significant Ownership of Invus Global Management, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
LXRX Lexicon Pharmaceuticals, Inc. Common Stock, par value $0.001 per share 36% $177,944,476 154,734,327 Artal Participations S.a r.l. 29 Jan 2026
SRRK Scholar Rock Holding Corporation Common Stock, par value $0.001 per share 11% $354,735,676 10,825,013 Invus Public Equities, L.P. 31 Dec 2024
IVA Inventiva S.A. Ordinary shares, nominal value Euro 0.01 per share 11% $49,037,031 +$24,518,517 14,814,813 +100% Invus Public Equities, L.P. 30 Jun 2025
RANI Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value 10% $4,910,990 9,825,911 Raymond Debbane 16 Oct 2025
BCAX Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share 9.6% $50,656,769 5,216,969 Raymond Debbane 30 Jun 2025
SLDB Solid Biosciences Inc. Common Stock, $0.001 par value per share 9.6% $27,216,371 +$13,457,391 7,415,905 +98% Raymond Debbane 31 Mar 2025
VTVT vTv Therapeutics Inc. Class A Common Stock, $0.01 par value per share 9.4% $9,179,310 +$1,051,154 393,098 +13% Raymond Debbane 30 Sep 2025
TENX Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share 9.4% $2,562,846 427,141 Raymond Debbane 26 Sep 2025
NBTX Nanobiotix S.A. Ordinary shares, nominal value Euro 0.03 per share 8.9% $13,545,053 4,232,829 Invus Public Equities, L.P. 31 Dec 2023
ENGN enGene Holdings Inc. Common Shares 6.3% $38,328,368 4,244,559 Raymond Debbane 21 Jan 2026
BCYC Bicycle Therapeutics plc Ordinary Shares, nominal value GBP 0.01 per share 6.3% $17,729,146 3,149,049 Raymond Debbane 25 Feb 2026
DBVT DBV Technologies S.A. Ordinary Shares, nominal value Euro 0.10 per share 6.2% $257,312,713 +$50,428,125 14,350,960 +24% Raymond Debbane 31 Dec 2025
TNGX Tango Therapeutics, Inc. Common Stock, $0.001 par value per share 6.1% $95,943,144 +$26,815,686 8,165,374 +39% Raymond Debbane 31 Dec 2025
NMRA Neumora Therapeutics, Inc. Common Stock, par value $0.0001 per share 5.4% $18,355,557 8,997,822 Raymond Debbane 13 Feb 2026
OLMA Olema Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share 5.1% $108,693,078 4,461,949 Raymond Debbane 16 Mar 2026
ABVX Abivax S.A. Ordinary Shares, nominal value Euro 0.01 per share 5% $469,347,122 -$177,185,644 3,922,995 -27% Invus Public Equities, L.P. 31 Dec 2025
VIGL Vigil Neuroscience, Inc. Common Stock, par value $0.0001 per share 4.9% $3,563,958 1,991,038 Raymond Debbane 31 Dec 2024
SYRS Syros Pharmaceuticals, Inc. Common Stock, $0.001 par value per share 3.8% $776,595 1,063,829 Invus Public Equities, L.P. 31 Dec 2024
GOSS Gossamer Bio, Inc. Common Stock, par value $0.0001 per share 2.8% $5,507,814 6,258,880 Invus Public Equities, L.P. 31 Dec 2024
KLRS Kalaris Therapeutics, Inc. Common Stock, $0.0001 par value per share 1.5% $754,533 282,586 Invus Public Equities, L.P. 30 Jun 2025
RZLT Rezolute, Inc. Common Stock, $0.001 par value per share 0% $0 -$11,541,900 0 -100% Invus Public Equities, L.P. 31 Dec 2025

Schedules 13D/G Reported by Invus Global Management, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored